This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
  • Latest Dividend: N/A
  • Latest Dividend Yield: N/A
  • Dividend Ex-Date: N/A
  • Price Earnings Ratio: -3.9218
  • Price Earnings Comparisons:
    INFI Sector Avg. S&P 500
    -3.92 0.00 28.64
  • Price Performance History
    (% change):
    3 Mo 1 Yr 3 Yr
    6.99% -27.91% 46.34%
  • GROWTH 12 Mo 3 Yr CAGR
    Revenue -100.00 -1.00 0.00
    Net Income 0.00 1.59 0.00
    EPS 0.00 0.42 0.00
  • Earnings for INFI:
    EBITDA -127,676,000
    REVENUE N/A
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (12/14) FY (12/15)
Average Estimate $-0.83 $-0.84 $-3.36 $-2.51
Number of Analysts 7 7 7 6
High Estimate $-0.72 $-0.59 $-2.51 $-1.82
Low Estimate $-0.93 $-0.98 $-3.80 $-3.47
Prior Year $-0.68 $-0.71 $-2.64 $-3.36
Growth Rate (Year over Year) -21.85% -17.91% -27.22% 25.27%
INFI News

INFI Infinity Pharmaceuticals Inc

Analysts Ratings for INFI

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 4 4 4 3
Moderate Buy 1 0 0 0
Hold 2 2 2 3
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
GET INFI ANALYST REPORT

Brokerage Partners

INFI Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs